Home › Modalities › Protein

Protein (72 companies)

Ticker	Company	Therapeutic areas	Programs	Lead stage	Programs
ABSI	Absci	DermatologyGI/Hepatology+1	6	Phase 1	7
ACIU	AC Immune	Neurology Rare	5	Phase 3	11
ACRS	Aclaris Therapeutics	DermatologyRespiratory	3	Phase 2	7
ABOS	Acumen Pharmaceuticals	Neurology	4	Phase 2	4
ADAG	Adagene	Oncology	9	Phase 2	9
ADCT	ADC Therapeutics	Oncology	5	Approved	5
ADMA	Adma Biologics	Infectious Disease	4	Approved	4
AGMB	Agomab Therapeutics	ImmunologyRespiratory Rare	2	Phase 2	4
AKBA	Akebia Therapeutics	HematologyOphthalmology+2 Rare	3	Approved	10
ANAB	AnaptysBio	DermatologyGI/Hepatology+2 Rare	6	Approved	6
ANNX	Annexon	HematologyNeurology+2 Rare	5	NDA Submitted	6
APGE	Apogee Therapeutics	DermatologyGI/Hepatology+1 Rare	9	Phase 2	9
APVO	Aptevo Therapeutics	Oncology	8	Phase 1	8
RCUS	Arcus Biosciences	DermatologyImmunology+1	2	Phase 3	6
BEAM	Beam Therapeutics	HematologyMetabolic+1 Rare	1	Phase 1	7
BCAX	Bicara Therapeutics	Oncology	4	Phase 3	4
BCTX	BriaCell Therapeutics	Oncology	1	Phase 3	8
CLDX	Celldex Therapeutics	DermatologyImmunology+1	7	Phase 3	7
CLYM	Climb Bio	HematologyImmunology+1 Rare	6	Phase 2	7
CHRS	Coherus Oncology	Oncology	4	Approved	4
CGEN	Compugen	Oncology	7	Phase 3	7
CNTB	Connect Biopharma	Respiratory	4	Phase 2	4
CRVS	Corvus Pharmaceuticals	DermatologyOncology	1	Phase 3	4
CBIO	Crescent Biopharma	Oncology	10	Phase 1	10
CUE	Cue Biopharma	Oncology	4	Phase 1	4
CGEM	Cullinan Therapeutics	HematologyImmunology+2 Rare	9	NDA Submitted	10
CYDY	CytoDyn	NeurologyOncology	3	Phase 2	3
CTMX	CytomX Therapeutics	Oncology	3	Phase 1	3
DBVT	DBV Technologies	GI/HepatologyImmunology Rare	3	NDA Submitted	3
DYN	Dyne Therapeutics	MetabolicNeurology Rare	1	NDA Submitted	10
ERAS	Erasca	Oncology	1	Phase 1	4
ETON	Eton Pharmaceuticals	GI/HepatologyMetabolic+1 Rare	1	Approved	14
EVMN	Evommune	DermatologyImmunology+1	2	Phase 2	6
EXEL	Exelixis	CardiovascularOncology	5	Approved	21
FBRX	Forte Biosciences	DermatologyGI/Hepatology	3	Phase 2	3
FBIO	Fortress Biotech	DermatologyHematology+1 Rare	3	Approved	12
IMTX	Immatics	Oncology	6	Phase 2	8
IBRX	ImmunityBio	Infectious DiseaseOncology	6	NDA Submitted	16
IMNM	Immunome	Oncology	7	NDA Submitted	9
IMVT	Immunovant	ImmunologyNeurology Rare	6	Phase 2	6
INAB	IN8bio	ImmunologyOncology	1	Phase 2	6
JBIO	Jade Biosciences	ImmunologyRenal Rare	6	Phase 2	6
JANX	Janux Therapeutics	Oncology	2	Phase 1	2
KOD	Kodiak Sciences	Ophthalmology	7	Phase 3	7
LRMR	Larimar Therapeutics	Neurology Rare	1	NDA Submitted	1
MDNAF	Medicenna Therapeutics	Oncology	8	Phase 3	9
NKTR	Nektar Therapeutics	DermatologyImmunology+2	11	Phase 2	11
NBP	NovaBridge Biosciences	OncologyOphthalmology	6	Phase 2	6
OCGN	Ocugen	Infectious DiseaseOphthalmology Rare	3	Phase 3	13
OCS	Oculis Holding	NeurologyOphthalmology	1	Phase 3	5
OMER	Omeros	HematologyNeurology+2 Rare	5	NDA Submitted	7
ORKA	Oruka Therapeutics	DermatologyImmunology Rare	6	Phase 2	6
OTLK	Outlook Therapeutics	Ophthalmology	3	NDA Submitted	3
PMN	ProMIS Neurosciences	Neurology Rare	6	Phase 1	6
SPRB	Spruce Biosciences	Metabolic Rare	2	Preclinical	2
SYRE	Spyre Therapeutics	Immunology	12	Phase 2	12
SMMT	Summit Therapeutics	Oncology	3	Phase 3	3
STRO	Sutro Biopharma	Oncology	4	Phase 1	4
TECX	Tectonic Therapeutic	Cardiovascular Rare	3	Phase 2	3
TGTX	Tg Therapeutics	Neurology Rare	3	Approved	4
TVTX	Travere Therapeutics	MetabolicRenal Rare	1	Approved	7
RARE	Ultragenyx Pharmaceutical	CardiovascularGI/Hepatology+2 Rare	5	Approved	12
VNDA	Vanda Pharmaceuticals	CardiovascularDermatology+6 Rare	1	Approved	26
VERA	Vera Therapeutics	Infectious DiseaseRenal Rare	6	Approved	8
VIR	Vir Biotechnology	Infectious DiseaseOncology Rare	9	Phase 3	10
VRDN	Viridian Therapeutics	Ophthalmology	6	Approved	6
VOR	Vor Biopharma	ImmunologyNeurology Rare	2	Phase 3	4
VYGR	Voyager Therapeutics	MetabolicNeurology Rare	1	Phase 1	7
XNCR	Xencor	HematologyImmunology+4 Rare	30	Approved	30
ZBIO	Zenas BioPharma	DermatologyImmunology+1 Rare	7	NDA Submitted	11
ZURA	Zura Bio	DermatologyImmunology Rare	4	Phase 2	4
ZYME	Zymeworks	OncologyRespiratory	11	Approved	11